Document is current
Any future updates will be listed below
-
Authors
Moura-Assis, Alexandre https://orcid.org/0000-0003-3300-3964
Plucińska, Kaja
Meseguer, David https://orcid.org/0000-0003-2977-4176
Baleisyte, Aiste
Chen, Bandy
Pellegrino, Kyle https://orcid.org/0000-0002-2917-9855
Parolari, Luca
Shaked, Jordan T.
Page, Keith J.
Barrows, Douglas W.
Carroll, Thomas S.
Grajales-Reyes, Jose G.
Na, Daxiang https://orcid.org/0000-0003-2432-5902
Rodriguez-Diaz, Amanda
Furtado, Jessica
Isaza, Juan Uribe https://orcid.org/0000-0003-1983-3363
Schiffer, Hans H. https://orcid.org/0009-0008-7050-0816
Chen, Yun
Sun, Huikai
Kaushal, Nidhi
Monenschein, Holger
Barker, Daniel F. https://orcid.org/0000-0003-1224-4232
Ortuño, María José
Renier, Nicolas https://orcid.org/0000-0003-2642-4402
Cohen, Paul https://orcid.org/0000-0002-2786-8585
Carlton, Mark
Heintz, Nathaniel
Brice, Nicola L.
Friedman, Jeffrey M. https://orcid.org/0000-0003-2152-0868
Schneeberger, Marc https://orcid.org/0000-0001-7369-104X
- License Information
-
More Information
Article History
Received: 30 July 2024
Accepted: 16 December 2025
First Online: 13 January 2026
Competing interests
: K.J.P., H.H.S., Y.C., H.S., N.K., H.M., D.F.B., M.C., and N.L.B. are/were employed by Cerevance and developed the CVN527 compound. The remaining authors declare no competing interests.
